Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kristina Barsten

Gastroenterology Virginia Beach, VA Doctor of Osteopathy

NPI 1386008472 CMS profile 11327130

1925 Glenn Mitchell Dr Ste 102, Virginia Beach, VA 23456

Open in the dashboard

General payments

$5,303

264 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristina Barsten of Virginia Beach, VA is reported in the CMS Open Payments database as having received $5,303 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,053 96
2024 General $2,046 92
2023 General $1,042 68
2022 General $162 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristina Barsten
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Kristina Barsten were reported at $2,053. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Kristina Barsten Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $0 $352 $106–$1,054 $132
2022 $162 $448 $129–$1,270 $149
2023 $1,042 $533 $150–$1,390 $160
2024 $2,046 $605 $160–$1,606 $164
2025 $2,053 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,635 99 payments
  2. Janssen Biotech, Inc. $667 34 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $386 19 payments
  4. QOL Medical, LLC $351 11 payments
  5. Ardelyx, Inc. $330 15 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $292 13 payments
  7. Regeneron Healthcare Solutions, Inc. $209 9 payments
  8. Celltrion USA Inc. $201 9 payments
  9. Pfizer Inc. $174 8 payments
  10. Ipsen Biopharmaceuticals, Inc $158 6 payments
  11. Other $902 41 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,267 262 payments
  2. Education $36 2 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $1,075 65 payments
  2. SKYRIZI Immunology $587 38 payments
  3. STELARA $564 30 payments
  4. SKYRIZI Immunology $493 30 payments
  5. HUMIRA $391 25 payments
  6. IBSRELA $330 15 payments
  7. ENTYVIO $328 15 payments
  8. SIMPONI ARIA $301 18 payments
  9. SIMPONI $301 18 payments
  10. CREON $258 12 payments
  11. Other $3,135 142 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

318

Median for Internal Medicine: 777

Drug cost

$75,989

Median for Internal Medicine: $73,373

Branded share of claims

52.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 53 $62,296
Movantik Naloxegol Oxalate Brand 21 $9,141
Omeprazole Generic 101 $1,328
Peg3350-Sod Sul-Nacl-Kcl-Asb-C Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 16 $1,101
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 49 $684
Dicyclomine Hcl Generic 17 $553
Pantoprazole Sodium Generic 13 $264
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 18 $263
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 11 $198
Famotidine Generic 19 $162

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$105,700

Medicare's payments for the services billed

Medicare patients

414

Average age 73

Services billed

764

296 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 34%
Chronic kidney disease 28%
Depression 26%
Heart failure 25%
Ischemic heart disease 25%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $216
$216 — —
Sucraid
  • QOL Medical, LLC $204
$204 — —
RINVOQ
  • AbbVie, Inc. $196
$196 — —
STELARA
  • Janssen Biotech, Inc. $172
$172 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $138
$138 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record